Stay updated with breaking news from Michael Erman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Structure Therapeutics' diabetes pill missed market expectations for weight loss in a mid-stage trial and also fell short of results from a similar treatment from rival Eli Lilly, sending the biotech...
By Michael Erman (Reuters) -Structure Therapeutics' diabetes pill missed market expectations for weight loss in a mid-stage trial and fell short of re...
By Michael Erman (Reuters) -Structure Therapeutics' diabetes pill missed market expectations for weight loss in a mid-stage trial and fell short of results ...
An experimental messenger RNA cancer vaccine developed by Moderna and Merck & Co paired with Merck's Keytruda cut the chance of recurrence or death from melanoma by half after three years, showing that benefits demonstrated a year ago have held up over time. The combination of the personalized cancer vaccine and Merck's blockbuster immunotherapy cut the risk of recurrence or death of the most deadly skin cancer by 49% compared with Keytruda alone in the midstage trial, the companies said.
WASHINGTON -The makers of a respiratory syncytial virus immunization for infants that has been in tight supply will deliver an additional 230,000 doses in January, the White House said on Thursday,... -December 14, 2023 at 04:38 pm EST - MarketScreener